Bristol Myers Squibb Company $BMY Stake Lifted by Sigma Planning Corp

Sigma Planning Corp increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 11.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 85,287 shares of the biopharmaceutical company’s stock after purchasing an additional 9,036 shares during the quarter. Sigma Planning Corp’s holdings in Bristol Myers Squibb were worth $5,318,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of BMY. Primecap Management Co. CA bought a new stake in Bristol Myers Squibb in the 2nd quarter worth about $1,436,115,000. Legal & General Group Plc bought a new position in Bristol Myers Squibb during the 2nd quarter valued at about $980,862,000. BlackRock Inc. lifted its stake in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares during the period. State Street Corp boosted its holdings in shares of Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after acquiring an additional 7,192,724 shares during the last quarter. Finally, Caisse de depot et placement du Quebec purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at about $243,646,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Promising lung-cancer results: Iza-bren doubled median progression-free survival versus chemotherapy in previously treated EGFR-mutated non-small-cell lung cancer in the Phase 3 PANKU-Lung01 study. The results strengthen the potential of BMY’s pipeline to offset declining legacy-drug revenue. Iza-bren lung-cancer Phase 3 results
• Positive Sentiment: Additional oncology momentum: A Phase 3 breast-cancer study reportedly showed Iza-bren reduced disease-progression risk by as much as 38%, while a Phase 2 trial of BMY and BioNTech’s pumitamig plus docetaxel produced a 36.7% response rate in advanced non-small-cell lung cancer. These programs could broaden BMY’s growth-drug portfolio. BMY cancer breakthrough Pumitamig Phase 2 data
• Positive Sentiment: Analyst remains bullish: Piper Sandler maintained an “overweight” rating and still sees substantial potential upside, despite reducing its price target from $82 to $78. Piper Sandler BMY rating
• Neutral Sentiment: Q3 earnings focus: Investors are weighing growth from newer medicines and improved Eliquis guidance against declines in BMY’s legacy portfolio ahead of quarterly results. Analysts are also monitoring revenue, margins and other operating metrics. BMY Q3 earnings outlook
• Negative Sentiment: Patent-cliff risk persists: Investors remain concerned that patent expirations for two blockbuster drugs could create a significant revenue gap before new medicines fully mature, despite BMY’s low valuation and dividend appeal. BMY patent-cliff analysis
• Negative Sentiment: Cautious earnings sentiment: Erste Group issued a pessimistic earnings outlook, adding to broader sell-side caution around BMY’s growth rate and post-patent-cliff prospects.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Guggenheim reissued a “buy” rating and set a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. UBS Group downgraded shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 13th. Finally, Piper Sandler dropped their target price on shares of Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating on the stock in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $65.50.

Bristol Myers Squibb Trading Up 0.1%

Shares of NYSE:BMY opened at $61.56 on Tuesday. The stock’s 50-day simple moving average is $63.20 and its two-hundred day simple moving average is $59.79. The stock has a market capitalization of $125.75 billion, a price-to-earnings ratio of 13.56, a PEG ratio of 0.31 and a beta of 0.19. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same quarter in the prior year, the firm earned $1.46 EPS. The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.51 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.05% of the stock is currently owned by insiders.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.